Jazz Pharmaceuticals

Explore the latest insights on Jazz Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Jazz Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its three drug candidates – BL-M07D1, BL-M05D1, and izalontamab bretecan – have been granted Breakthrough Therapy Designation (BTD) by the Center…

September 28, 2026

$Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies$

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

September 28, 2026

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

September 28, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals